Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | EVP & Gen. Counsel & Sec. | May 07, 2026 | May 12, 2026 |
| DANAHER CORP /DE/DHR · Entity 2871 | Senior VP & GC | May 19, 2015 | May 20, 2015 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,712 |
Reported balance
After 2026-05-07 transaction · row 1
1 source rowRow 1 · 2026-05-07 · Tax withholding · Disposed 499 · Balance 39,712 F1: These shares include 311 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include 311 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
DANAHER CORP /DE/
Report date May 19, 2015 · Filed May 20, 2015
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,606 |
Ending reported balance
After 2015-05-19 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2015-05-19 · Exercise / conversion · Acquired 11,926 · Balance 39,032 Row 2 · 2015-05-19 · Exercise / conversion · Acquired 25,806 · Balance 64,838 Row 3 · 2015-05-19 · Sale · Disposed 4,426 · Balance 60,412 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.00 to $87.02, inclusive. The reporting person undertakes to provide to Danaher Corporation, any securityholder of Danaher Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes to this Form 4. Row 4 · 2015-05-19 · Sale · Disposed 18,909 · Balance 41,503 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.00 to $87.02, inclusive. Row 5 · 2015-05-19 · Sale · Disposed 6,897 · Balance 34,606 |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.59 · Expires 2021-02-23 | Direct | 0 |
Reported balance
After 2015-05-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2015-05-19 · Exercise / conversion · Disposed 25,806 · Balance 0 F3: One-third of the options granted vested on each of the third, fourth and fifth anniversaries of the grant date, which was February 23, 2011. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.48 · Expires 2022-02-23 | Direct | 0 |
Reported balance
After 2015-05-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2015-05-19 · Exercise / conversion · Disposed 11,926 · Balance 0 F4: One-third of the options granted vested on each of the third, fourth and fifth anniversaries of the grant date, which was February 23, 2012. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.00 to $87.02, inclusive. The reporting person undertakes to provide to Danaher Corporation, any securityholder of Danaher Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes to this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.00 to $87.02, inclusive.
F3: One-third of the options granted vested on each of the third, fourth and fifth anniversaries of the grant date, which was February 23, 2011.
F4: One-third of the options granted vested on each of the third, fourth and fifth anniversaries of the grant date, which was February 23, 2012.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2026 Filed May 12, 2026 00:00 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 499 | $331.11 | $165,223.89 |
DisclosureSEC source: 0000318154-26-000086 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,712 F1 · price: These shares include 311 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 06, 2026 Filed May 8, 2026 00:59 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 408 | $329.59 | $134,472.72 |
DisclosureSEC source: 0000318154-26-000078 · form4.xml · nonDerivative · entry 2 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,211 F2 · balance_after: These shares include 370 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 05, 2026 Filed May 8, 2026 00:59 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 17,022 | $329.59 Strike: $329.59 | $5,610,280.98 |
DisclosureSEC source: 0000318154-26-000078 · form4.xml · derivative · entry 3 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,022 Underlying: Common Stock · 17,022 shares Expires 2036-05-05 F3 · derivative.exercise_date: These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027. Read SEC document |
| May 05, 2026 Filed May 8, 2026 00:59 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 2,609 | $0.00 | $0.00 |
DisclosureSEC source: 0000318154-26-000078 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,619 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| May 02, 2026 Filed May 6, 2026 00:07 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 610 | $329.82 | $201,190.20 |
DisclosureSEC source: 0000318154-26-000062 · form4.xml · nonDerivative · entry 2 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,010 F1 · balance_after: These shares include 395 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2026 Filed May 6, 2026 00:07 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 647 | $329.82 | $213,393.54 |
DisclosureSEC source: 0000318154-26-000062 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,620 Read SEC document |
| March 16, 2026 Filed Mar 19, 2026 00:31 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 5,353 | $366.21 | $1,960,322.13 |
DisclosureSEC source: 0000318154-26-000027 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,267 F1 · balance_after: These shares include 659 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 01:22 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 10,723 | $0.00 | $0.00 |
DisclosureSEC source: 0000318154-26-000016 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,478 F1 · balance_after: These shares include 590 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 06, 2025 Filed May 9, 2025 00:53 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 20,554 | $270.44 Strike: $270.44 | $5,558,623.76 |
DisclosureSEC source: 0001127602-25-013781 · form4.xml · derivative · entry 2 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,554 Underlying: Common Stock · 20,554 shares Expires 2035-05-06 F3 · derivative.exercise_date: These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/6/2026. Read SEC document |
| May 06, 2025 Filed May 9, 2025 00:53 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013781 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,517 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/6/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 352 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2025 Filed May 7, 2025 00:10 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 592 | $283.78 | $167,997.76 |
DisclosureSEC source: 0001127602-25-013528 · form4.xml · nonDerivative · entry 2 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,337 F1 · balance_after: These shares include 352 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2025 Filed May 7, 2025 00:10 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 609 | $283.78 | $172,822.02 |
DisclosureSEC source: 0001127602-25-013528 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,929 Read SEC document |
| April 30, 2025 Filed May 3, 2025 01:26 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 728 | $288.56 | $210,071.68 |
DisclosureSEC source: 0001127602-25-013281 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,922 F1 · balance_after: These shares include 536 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 17, 2025 Filed Mar 20, 2025 00:17 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 3,150 | $313.71 | $988,186.50 |
DisclosureSEC source: 0001127602-25-010055 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,266 F1 · balance_after: These shares include 710 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:58 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 6,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-008423 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,293 F1 · balance_after: These shares include 634 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 02:52 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 25,045 | $0.00 Strike: $156.35 | $0.00 |
DisclosureSEC source: 0001127602-25-003984 · form4.xml · derivative · entry 3 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,045 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 02:52 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 25,045 | $293.12 | $7,341,122.78 |
DisclosureSEC source: 0001127602-25-003984 · form4.xml · nonDerivative · entry 2 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,987 F2 · price: The price reported is an average price. Full information regarding the number of shares sold at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. F3 · balance_after: These shares include 634 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 02:52 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 25,045 | $156.35 | $3,915,785.75 |
DisclosureSEC source: 0001127602-25-003984 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 23:17 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 6,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028802 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,903 F1 · kind: These shares were gifted by the reporting person and the reporting person's spouse to two irrevocable trusts for the benefit of the reporting person's adult children. Neither the reporting person nor the reporting person's spouse are trustees of the trusts or otherwise have the power to vote or dispose of the assets held in such trusts. F2 · balance_after: Shares directly beneficially owned also include 550 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested restricted stock units (RSUs) and are paid out in shares of the Company's common stock on a one-to-one basis upon vesting of the associated RSUs with a cash payment for any remaining fractional share amount. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:03 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 18,603 | $300.30 Strike: $300.30 | $5,586,480.90 |
DisclosureSEC source: 0001127602-24-014853 · form4.xml · derivative · entry 2 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,603 Underlying: Common Stock · 18,603 shares Expires 2034-05-07 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:03 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 2,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014853 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,186 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,291 RSUs which will vest on 4/30/2025; 2,263 RSUs which will vest in installments of 1,114 each on 5/2/2025, and one installment of 1,149 on 5/2/2026; 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027; and 2,863 RSUs which will vest in installments of 944 on 5/7/2026, 945 on 5/7/2027, and 974 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 403 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 05, 2024 Filed May 8, 2024 00:33 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 632 | $311.29 | $196,735.28 |
DisclosureSEC source: 0001127602-24-014507 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,323 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,291 RSUs which will vest on 4/30/2025; 2,263 RSUs which will vest in installments of 1,114 each on 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 403 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2024 Filed May 3, 2024 23:19 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 591 | $277.37 | $163,925.67 |
DisclosureSEC source: 0001127602-24-014192 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,955 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,122 RSUs which will vest on 5/5/2024; 1,291 RSUs which will vest on 4/30/2025; 2,263 RSUs which will vest in installments of 1,114 each on 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 553 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:59 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 686 | $276.38 | $189,596.68 |
DisclosureSEC source: 0001127602-24-014026 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,546 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,122 RSUs which will vest on 5/5/2024; 1,291 RSUs which will vest on 4/30/2025; 3,377 RSUs which will vest in two installments of 1,114 each on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 628 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 18, 2024 Filed Mar 21, 2024 00:04 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 5,879 | $268.87 | $1,580,686.73 |
DisclosureSEC source: 0001127602-24-010850 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,232 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,122 RSUs which will vest on 5/5/2024; 2,544 RSUs which will vest in installments of 1,253 on 4/30/2024 and 1,291 on 4/30/2025; 3,377 RSUs which will vest in two installments of 1,114 each on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 756 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:26 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 11,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-009241 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,925 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,122 RSUs which will vest on 5/5/2024; 2,544 RSUs which will vest in installments of 1,253 on 4/30/2024 and 1,291 on 4/30/2025; 3,377 RSUs which will vest in two installments of 1,114 each on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 666 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 08, 2023 Filed Nov 14, 2023 01:30 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 10,000 | $272.81 | $2,728,136.00 |
DisclosureSEC source: 0001127602-23-027292 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,078 F1 · balance_after: The price reported is an average price. The prices ranged from $272.79 to $272.96 per share. Full information regarding the number of shares purchased at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,122 RSUs which will vest on 5/5/2024; 2,544 RSUs which will vest in installments of 1,253 on 4/30/2024 and 1,291 on 4/30/2025; 3,377 RSUs which will vest in two installments each of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 579 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 23:43 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,751 | $255.70 | $447,730.70 |
DisclosureSEC source: 0001127602-23-026804 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,078 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,122 RSUs which will vest on 5/5/2024; 2,544 RSUs which will vest in installments of 1,253 on 4/30/2024 and 1,291 on 4/30/2025; 3,377 RSUs which will vest in two installments each of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 579 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 05, 2023 Filed May 9, 2023 23:14 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 592 | $231.89 | $137,278.88 |
DisclosureSEC source: 0001127602-23-015045 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,573 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,120 RSUs which will vest on 11/1/2023; 1,122 RSUs which will vest on 5/5/2024; 2,544 RSUs which will vest in installments of 1,253 on 4/30/2024 and 1,291 on 4/30/2025; 3,377 RSUs which will vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 734 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2023 Filed May 5, 2023 00:25 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 602 | $235.97 | $142,053.94 |
DisclosureSEC source: 0001127602-23-014607 · form4.xml · nonDerivative · entry 2 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,165 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 3,120 RSUs which will vest on 11/1/2023; 2,211 RSUs which will vest in installments of 1,089 on 5/5/2023 and 1,122 on 5/5/2024; 2,544 RSUs which will vest in installments of 1,253 on 4/30/2024 and 1,291 on 4/30/2025; 3,377 RSUs which will vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 838 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:25 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 28,666 | $0.00 Strike: $235.97 | $0.00 |
DisclosureSEC source: 0001127602-23-014607 · form4.xml · derivative · entry 3 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,666 Underlying: Common Stock · 28,666 shares Expires 2033-05-02 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:25 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014607 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,767 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| April 30, 2023 Filed May 3, 2023 00:19 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 664 | $239.74 | $159,187.36 |
DisclosureSEC source: 0001127602-23-014151 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,377 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,074 RSUs which will vest on 5/3/2023; 3,120 RSUs which will vest on 11/1/2023; 2,211 RSUs which will vest in installments of 1,089 on 5/5/2023 and 1,122 on 5/5/2024; 2,544 RSUs which will vest in installments of 1,253 on 4/30/2024 and one installment of 1,291 on 4/30/2025; and 3,377 RSUs which will vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 975 DEs granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 23:07 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 3,785 | $234.57 | $887,847.45 |
DisclosureSEC source: 0001127602-23-010915 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,041 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,074 RSUs which will vest on 5/3/2023; 3,120 RSUs which will vest on 11/1/2023; 2,211 RSUs which will vest in installments of 1,089 on 5/5/2023 and 1,122 on 5/5/2024; 3,797 RSUs which will vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025; and 3,377 RSUs which will vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,057 DEs granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 00:17 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 7,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-009503 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,620 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,074 RSUs which will vest on 5/3/2023; 3,120 RSUs which will vest on 11/1/2023; 2,211 RSUs which will vest in installments of 1,089 on 5/5/2023 and 1,122 on 5/5/2024; 3,797 RSUs which will vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025; and 3,377 RSUs which will vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 922 DEs granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 01, 2022 Filed Nov 1, 2022 23:46 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,644 | $270.35 | $444,455.40 |
DisclosureSEC source: 0001127602-22-024662 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,963 F1 · shares: 1,644 shares issuable upon the vesting of Restricted Stock Units (RSUs) and related Dividend Equivalents (DEs) on 11/1/2022 were withheld by the Company to cover related tax withholding obligations. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,074 RSUs which will vest on 5/3/2023; 3,120 RSUs which will vest on 11/1/2023; 2,211 RSUs which will vest in installments of 1,089 on 5/5/2023 and 1,122 on 5/5/2024; 3,797 RSUs which will vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025; and 3,377 RSUs which will vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 825 DEs granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 12, 2022 Filed May 13, 2022 00:11 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-014292 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,333 F1 · kind: The transaction reported involved a gift by the reporting person of shares of the Company's common stock to a charitable donor advised fund. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,074 RSUs which will vest on 5/3/2023; 6,148 RSUs which vest in one installment of 3,028 on 11/1/2022 and one installment of 3,120 on 11/1/2023; 2,211 RSUs which vest in installments of 1,089 on 5/5/2023 and 1,122 on 5/5/2024; 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025; and 3,377 RSUs which vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 835 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 10, 2022 Filed May 10, 2022 23:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 13,500 | $241.81 | $3,264,453.90 |
DisclosureSEC source: 0001127602-22-014038 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,333 F1 · price: The price reported is an average price. The prices ranged from $241.73 to $241.97 per share. Full information regarding the number of shares purchased at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,074 RSUs which will vest on 5/3/2023; 6,148 RSUs which vest in one installment of 3,028 on 11/1/2022 and one installment of 3,120 on 11/1/2023; 2,211 RSUs which vest in installments of 1,089 on 5/5/2023 and 1,122 on 5/5/2024; 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025; and 3,377 RSUs which vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 835 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 05, 2022 Filed May 9, 2022 23:03 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 574 | $236.10 | $135,521.40 |
DisclosureSEC source: 0001127602-22-013870 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,833 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,074 RSUs which will vest on 5/3/2023; 6,148 RSUs which vest in one installment of 3,028 on 11/1/2022 and one installment of 3,120 on 11/1/2023; 2,211 RSUs which vest in installments of 1,089 on 5/5/2023 and 1,122 on 5/5/2024; 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025; and 3,377 RSUs which vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 835 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2022 Filed May 4, 2022 23:51 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 566 | $230.92 | $130,700.72 |
DisclosureSEC source: 0001127602-22-013345 · form4.xml · nonDerivative · entry 2 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,407 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,074 RSUs which will vest in one installment of 1,074 on 5/3/2023; 6,148 RSUs which vest in one installment of 3,028 on 11/1/2022 and one installment of 3,120 on 11/1/2023; 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024; 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025; and 3,377 RSUs which vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and 1,149 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 902 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2022 Filed May 4, 2022 23:51 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 27,574 | $0.00 Strike: $230.92 | $0.00 |
DisclosureSEC source: 0001127602-22-013345 · form4.xml · derivative · entry 3 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,574 Underlying: Common Stock · 27,574 shares Expires 2032-05-02 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively. Read SEC document |
| May 02, 2022 Filed May 4, 2022 23:51 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013345 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,973 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 22:39 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 599 | $249.87 | $149,672.13 |
DisclosureSEC source: 0001127602-22-012759 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,596 F1 · balance_after: These shares include the following Restricted Stock Units granted under the Company's equity plans: 2,116 RSUs which vest in installments of 1,042 on 5/3/2022 and 1,074 on 5/3/2023; 6,148 RSUs which vest in one installment of 3,028 on 11/1/2022 and one installment of 3,120 on 11/1/2023; 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024; and 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 999 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 21:40 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 3,496 | $235.86 | $824,566.56 |
DisclosureSEC source: 0001127602-22-010188 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,195 F1 · balance_after: These shares include the following Restricted Stock Units granted under the Company's equity plans: 1,073 RSUs which will vest on 4/27/2022; 2,116 RSUs which vest in installments of 1,042 on 5/3/2022 and 1,074 on 5/3/2023; 6,148 RSUs which vest in one installment of 3,028 on 11/1/2022 and one installment of 3,120 on 11/1/2023; 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024; and 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,133 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:26 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 6,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-008133 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,487 F1 · balance_after: These shares include the following Restricted Stock Units granted under the Company's equity plans: 1,073 RSUs which will vest on 4/27/2022; 2,116 RSUs which vest in installments of 1,042 on 5/3/2022 and 1,074 on 5/3/2023; 6,148 RSUs which vest in one installment of 3,028 on 11/1/2022 and one installment of 3,120 on 11/1/2023; 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024; and 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 987 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:21 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,591 | $206.97 | $329,289.27 |
DisclosureSEC source: 0001127602-21-028363 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,353 F1 · balance_after: These shares include the following Restricted Stock Units granted under the Company's equity plans: 1,073 RSUs which will vest on 4/27/2022; 2,116 RSUs which vest in installments of 1,042 on 5/3/2022 and 1,074 on 5/3/2023; 6,148 RSUs which vest in one installment of 3,028 on 11/1/2022 and one installment of 3,120 on 11/1/2023; 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024; and 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 845 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2021 Filed May 4, 2021 23:15 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 548 | $239.64 | $131,322.72 |
DisclosureSEC source: 0001127602-21-015352 · form4.xml · nonDerivative · entry 3 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,633 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,073 RSUs which will vest on 4/27/2022; 2,116 RSUs which vest in installments of 1,042 on 5/3/2022 and 1,074 on 5/3/2023; 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023; 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024; and 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 712 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 01, 2021 Filed May 4, 2021 23:15 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 581 | $239.64 | $139,230.84 |
DisclosureSEC source: 0001127602-21-015352 · form4.xml · nonDerivative · entry 2 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,181 Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:15 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 32,971 | $0.00 Strike: $239.64 | $0.00 |
DisclosureSEC source: 0001127602-21-015352 · form4.xml · derivative · entry 4 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,971 Underlying: Common Stock · 32,971 shares Expires 2031-04-30 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:15 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015352 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,762 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.